What is the current valuation of Vor BioPharma’s Tremtelectogene Empogeditemcel

The revenue for Tremtelectogene Empogeditemcel is expected to reach an annual total of $91 mn by 2039 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.

Tremtelectogene Empogeditemcel Overview

Trem-cel (VOR-33) is under development for the treatment of relapsed and refractory acute myeloid leukemia (AML), myelodysplastic syndrome and myeloproliferative neoplasm . It is administered via parenteral route. The therapeutic candidate comprises allogeneic CRISPR/Cas9 genome-edited hematopoietic stem and progenitor cell (HSPC).It is developed based on eHSC technology.

Vor BioPharma Overview

Vor BioPharma, a subsidiary of Puretech Health Plc, is a clinical-stage cell therapy company that develops therapies for the treatment of hematological malignancies. The company’s pipeline products include Trem-cel (formerly VOR33), is an eHSC product candidate created by genetically modifying healthy donor HSCs in order to remove the CD33 surface target protecting them from a targeted therapy post-transplant. Vor BioPharma‘s other pipelines include VCAR33 (Allogeneic), VCAR33 (Autologous), Trem-cel + VCAR33, Treatment System and CD33-CLL1 Treatment System. Vor BioPharma is headquartered in Cambridge, Massachusetts, the US.

The operating loss of the company was US$93.4 million in FY2022, compared to an operating loss of US$69 million in FY2021. The net loss of the company was US$92.1 million in FY2022, compared to a net loss of US$68.9 million in FY2021.

For a complete picture of Tremtelectogene Empogeditemcel’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.

Sign up for our daily news round-up!

Give your business an edge with our leading industry insights.

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.